In vivo and in vitro immune responses against Francisella tularensis vaccines are comparable among Fischer 344 rat substrains. 2023

Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
Laboratory of Mucosal Pathogens and Cellular Immunology, Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.

Identifying suitable animal models and standardizing preclinical methods are important for the generation, characterization, and development of new vaccines, including those against Francisella tularensis. Non-human primates represent an important animal model to evaluate tularemia vaccine efficacy, and the use of correlates of vaccine-induced protection may facilitate bridging immune responses from non-human primates to people. However, among small animals, Fischer 344 rats represent a valuable resource for initial studies to evaluate immune responses, to identify correlates of protection, and to screen novel vaccines. In this study, we performed a comparative analysis of three Fischer rat substrains to determine potential differences in immune responses, to evaluate methods used to quantify potential correlates of protection, and to evaluate protection after vaccination. To this end, we took advantage of data previously generated using one of the rat substrains by evaluating two live vaccines, LVS and F. tularensis SchuS4-ΔclpB (ΔclpB). We compared immune responses after primary vaccination, adaptive immune responses upon re-stimulation of leukocytes in vitro, and sensitivity to aerosol challenge. Despite some detectable differences, the results highlight the similarity of immune responses to tularemia vaccines and challenge outcomes between the three substrains, indicating that all offer acceptable and comparable approaches as animal models to study Francisella infection and immunity.

UI MeSH Term Description Entries

Related Publications

Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
September 2017, Journal of visualized experiments : JoVE,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
June 2007, Annals of the New York Academy of Sciences,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
July 2009, Vaccine,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
January 2012, PloS one,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
June 2004, Expert review of vaccines,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
April 2009, Microbial pathogenesis,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
January 2015, PloS one,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
April 2019, Journal of bacteriology,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
July 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
Roberto De Pascalis, and Varunika Bhargava, and Scott Espich, and Terry H Wu, and H Carl Gelhaus, and Karen L Elkins
February 2017, The American journal of pathology,
Copied contents to your clipboard!